New treatment strategy aims to stop rare liver cancer
An OHSU surgeon’s innovative approach targets deadly cholangiocarcinoma of the liver. Jerry Widawski knew the statistics were not in his favor. At age 68, he was diagnosed with a rare...
An OHSU surgeon’s innovative approach targets deadly cholangiocarcinoma of the liver. Jerry Widawski knew the statistics were not in his favor. At age 68, he was diagnosed with a rare...
OHSU's immunotherapy and cell transplant team has earned national recognition for its expertise and experience providing CAR T-cell therapy — the breakthrough treatment for children with leukemia...
Restoring tumor-specific immunity is a treatment strategy that has worked well, but only against some cancers. Research led by OHSU oncologist Julie Graff, M.D., revived hope that the approach may...
When chemotherapy stops working and stem-cell transplantation fails or is not an option, medicine has little to offer patients with the aggressive blood cancer called diffuse large B-cell lymphoma,...
Cancer researchers at OHSU have been awarded $1 million to test the idea that adjusting the diversity of bacteria inhabiting the intestines could make aggressive prostate cancers more responsive to...
Scrutinizing the immune cells infiltrating a tumor may reveal the cancer's vulnerability or resistance to immune-based therapies. Cancer immune therapies have delivered life-saving, long-lasting...